# Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

> **NCT07727668** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shambavi Richard** · enrollment: 22 (estimated)

## Conditions studied

- Multiple Myeloma
- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Iberdomide
- **PROCEDURE:** CAR-T Leukapheresis
- **PROCEDURE:** CAR-T Infusion

## Key facts

- **NCT ID:** NCT07727668
- **Lead sponsor:** Shambavi Richard
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-07
- **Final completion:** 2031-07
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2026-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07727668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07727668, "Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07727668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*